AGTC Appoints Regulatory Expert, Janet C. Rae , RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials - - Company on track to provide multiple data readouts for its XLRP
- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules - GAINESVILLE, Fla. and CAMBRIDGE, Mass.
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
-Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting
-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- -Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- -Data from a subset of Group 4 patients available for
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass. , May 03, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
